Update to Fact Sheets of Paxlovid (Nirmatrelvir 300mg co-packaged with Ritonavir 100mg) tablets with new safety information and microbiological data

A Dear Healthcare Professional Letter has been issued by Pfizer Private Limited to inform healthcare professionals of updates to the Paxlovid Fact Sheets for Healthcare Providers and Patients/Caregivers. The updates to the Fact Sheets include the addition of anaphylaxis as adverse reaction, addition of new drug interactions and antiviral data. Healthcare professionals are advised to assess patient's medication and supplement list before starting Paxlovid treatment, and to inform patients to discontinue Paxlovid immediately if they experience any symptoms of allergic reactions. Please refer to the letter for details.
Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

15 Dec 2022

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.